Pasithea Therapeutics To Present New Preclinical Data Showing PAS-004 Strongly Inhibiting NRAS Cancer Cell Lines
Portfolio Pulse from Benzinga Newsdesk
Pasithea Therapeutics announced new preclinical data showing that PAS-004 strongly inhibits NRAS cancer cell lines.
May 28, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pasithea Therapeutics announced new preclinical data showing that PAS-004 strongly inhibits NRAS cancer cell lines.
The announcement of promising preclinical data for PAS-004 could boost investor confidence in Pasithea Therapeutics, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100